ERH在人脑胶质瘤中的表达及其与病人预后的关系

目的 探讨未成熟同源蛋白增强子（ERH）在人脑胶质瘤组织中的表达及其与病人生存预后的关系。方法 免疫组织化学染色法检测2012年5月至2017年5月手术切除的121例胶质瘤组织和2012年5月~2017年5月颅脑损伤内减压术中切除的40例正常脑组织中ERH的表达水平。根据染色结果将胶质瘤分为高表达组和低表达组。采用多因素Cox比例回归风险模型分析胶质瘤病人总生存期（OS）和无进展生存期（PFS）的影响因素。结果 正常脑组织ERH高表达率（15.00%，6/40）明显低于胶质瘤组织（61.16%，74/121；P<0.05）。多因素Cox比例回归风险模型分析结果显示，WHO分级Ⅲ~Ⅳ级和ERH高表达是胶质瘤病人OS和PFS较短的独立影响因素（P<0.05）。生存曲线分析显示低表达组OS和PFS均明显高于高表达组（P<0.05）。结论 ERH在胶质瘤组织中高表达，并且与病人不良生存预后和肿瘤进展有关。

Expression of enhancer of rudimentary homolog in glioma tissues and its relationship with glioma patients’ prognoses

Objective To explore the expression of enhancer of rudimentary homolog (ERH) in glioma tissues and its relationship with the survival prognoses of glioma patients. Methods Immunohistochemical staining was used to detect the expression level of ERH in 121 glioma tissues obtained from 121 glioma patients underwent surgery from May 2012 to May 2017 and in 40 normal brain tissues obtained from 40 traumatic brain injury patients underwent decompressive craniectomy from May 2012 to May 2017. According to the staining results, the patients with glioma were divided into high expression group and low expression group. The multivariate Cox proportional regression risk model was used to analyze the overall survival (OS) and progression-free survival (PFS) of glioma patients. Results The high expression rate of ERH in normal brain tissue (15.00%, 6/40) was significantly lower than that (61.16%, 74/121) in glioma tissue (P<0.05). The results of multivariate Cox proportional regression risk model analysis showed that WHO grades Ⅲ~Ⅳ and high ERH expression were independent risk factors for shorter OS and PFS in patients with glioma (P<0.05). The OS and PFS of the low expression group were significantly higher than those of the high expression group (P<0.05). Conclusion ERH is highly expressed in glioma tissues, which is related to the poor survival prognoses of patients.